Clinical trial · no report yet · Phase 3
KEYLYNK-001
Study of Chemotherapy With Pembrolizumab (MK-3475) Followed by Maintenance With Olaparib (MK-7339) for the First-Line Treatment of Women With BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (MK-7339-001/KEYLYNK-001/ENGOT-ov43/GOG-3036)
- NCT03740165 ↗
- Completed
- Merck Sharp & Dohme LLC
- Standard
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 10 | |
| Podcasts | 7 | |
| X threads | 3 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase 3, Double-Blind Study of Chemotherapy With or Without Pembrolizumab Followed by Maintenance With Olaparib or Placebo for the First-Line Treatment of BRCA Non-mutated Advanced Epithelial Ovarian Cancer (EOC) (KEYLYNK-001 / ENGOT-ov43 / GOG-3036)
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Neoplasms
- Interventions
- Pembrolizumab; Placebo for pembrolizumab; Carboplatin; Paclitaxel; Olaparib; Placebo for olaparib; Bevacizumab; Docetaxel
- Arms
- Carboplatin + Paclitaxel + Pembrolizumab + Olaparib · Experimental
- Carboplatin + Paclitaxel + Pembrolizumab · Experimental
- Carboplatin + Paclitaxel · Active comparator
- Enrollment
- 1,367
- Primary outcomes
- Progression-Free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by the Investigator in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Tumors (Combined Positive Score [CPS]≥10)
- PFS Per RECIST 1.1 as Assessed by the Investigator in All Participants
- Sponsor
- Merck Sharp & Dohme LLC with European Network of Gynaecological Oncological Trial Groups (ENGOT), Gynecologic Oncology Group
- Start
- Dec 18, 2018
- Primary completion
- Aug 26, 2024
- Results posted
- Yes
- Registry record
- NCT03740165 · updated Aug 19, 2026
Publications
linked from the registry- Vergote I, Cibula D, Powell M, Laenen A, Nieuwenhuysen EV, Topuz S, Gonzalez-Martin A, Fujiwara K, Safina S, Bagameri A, Oliver M, Lee JY, Salutari V, Korach J, Lu CH, Madry R, Vulsteke C, Colombo N, Sehouli J, Klat J, Ruiz EY, Gilbert L, Pautier P, Pardo B, Kridelka F, Wei J, Toker S, Yamada K, Coleman RL; ENGOT-OV43/GOG-3036/KEYLYNK-001 investigators. Chemotherapy with or without pembrolizumab followed by maintenance pembrolizumab with or without olaparib as first-line treatment of patients with advanced BRCA non-mutated epithelial ovarian cancer (ENGOT-OV43/GOG-3036/KEYLYNK-001): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2026 Sep 7:S1470-2045(26)00223-8. doi: 10.1016/S1470-2045(26)00223-8. Online ahead of print. PubMed 42705254